Welcome to our dedicated page for MDB Capital Holdings LLC-A news (Ticker: MDBH), a resource for investors and traders seeking the latest updates and insights on MDB Capital Holdings LLC-A stock.
MDB Capital Holdings, LLC (NASDAQ: MDBH) is an investment holding company and public venture platform in the investment banking and securities dealing industry. News and press releases about MDB Capital highlight its focus on launching early-stage and disruptive "Big Idea" companies through public venture capital, as well as developments across its subsidiaries such as MDB Capital and PatentVest.
Readers following MDBH news can expect updates on private placements, initial public offerings, and post-IPO offerings for emerging companies that align with MDB’s investment criteria. Recent announcements describe offerings and planned offerings for companies in areas such as biopharmaceuticals and consumer products, along with the expansion of MDB’s pipeline of early-stage, disruptive companies and partnerships with investor groups and registered investment advisers.
News related to PatentVest, a division of MDB Capital Holdings, features IP-focused research and strategy. PatentVest issues PatentVest Pulse reports that analyze intellectual property and competitive landscapes in sectors including quantum computing, the space economy, and cardiac diagnostics. These reports use patent data to examine leadership, defensible IP positions, and commercialization progress across innovation-driven markets.
Additional MDBH news items cover conference presentations, investor webinars, and corporate updates, including plans to spin out PatentVest as an independent public company. For investors and observers, the MDBH news feed provides insight into the company’s ongoing financings, its role in public venture capital, and its IP-centered analysis of emerging technology markets.
MDB Capital Holdings (NASDAQ: MDBH) provided a 2025 full-year update and shareholder letter on March 31, 2026, detailing asset positions, cash, expenses, and strategic spin-outs.
Key points: an EXOZ stake valued at ~$30 million, Paulex seed funding of $19 million, year-end cash of ~$22.3 million, annual fixed operating expenses of ~$10 million, and net cash used of ~$5.7 million.
PatentVest (MDBH) released a Pulse report, “The Amylin Renaissance,” on March 31, 2026, detailing a rapid commercialization shift in amylin-based obesity therapies.
The report documents nearly 40 amylin receptor agonist programs, more than $19 billion in deal value committed over the past 18 months, clinical data showing up to 20%+ weight loss, an approaching FDA decision for a GLP-1/amylin combo, and growing oral small-molecule efforts. It emphasizes patent strategy as a decisive competitive factor.
PatentVest (NYSE:MDBH) added a new IP Legal Insights article on March 30, 2026, addressing patenting strategies for AI-assisted inventions. The piece, by Sarah Cork, Ph.D., Senior Patent Attorney, covers Section 101 eligibility, inventorship issues, claim drafting, and recent USPTO guidance shaping AI patent evaluation.
The article emphasizes demonstrating technological improvements, practical applications, and clear human contribution when seeking protection for AI-driven innovations.
PatentVest (MDBH) announced a strategic engagement with Life Seal Vascular on March 30, 2026, accepting equity as partial consideration for IP intelligence and legal services. The deal pairs PatentVest's proprietary IP platform with Life Seal Vascular's vascular device technology and signals a long-term commercial and strategic alignment.
The partnership aims to map competitive patent landscapes, identify patenting opportunities and risks, and inform R&D, licensing, and commercialization decisions for Life Seal Vascular.
MDB Capital Holdings (NASDAQ: MDBH) will host a Zoom webinar on Tuesday, March 31, 2026 at 4:30 p.m. ET to discuss its fourth quarter and full year 2025 results.
Christopher Marlett, CEO and Co-Founder, will lead the call; a press release with results will be issued prior to the webinar. Investors can pre-register for the Zoom webinar or access the live webcast via MDB’s investor relations site at https://investors.mdb.com/.
PatentVest (MDBH) announced on March 11, 2026 the completion of a strategic intellectual property engagement with Porosome Therapeutics to evaluate and strengthen its IP portfolio for secretion-restoration therapeutics.
PatentVest delivered an IP portfolio audit, global patent landscape analyses, competitive benchmarking, and partner assessment, and found Porosome Therapeutics has a distinct position in structural porosome reconstitution. Porosome plans additional filings covering organoid models, novel peptides, and small-molecule innovations to expand its IP estate.
PatentVest (Nasdaq: MDBH) released a PatentVest Pulse report, “The Oral Small-Molecule GLP-1 Race: Beyond Orforglipron,” analyzing 1,200+ patent documents across 50 programs to assess patent depth and long-term exclusivity.
Key findings: clinical efficacy converging at 12–16% weight loss, $71 billion injectable GLP-1 market, $47 billion in GLP-1 deal value since 2023, and looming patent cliffs for semaglutide (2031) and tirzepatide (2036).
MDB Capital Holdings (NASDAQ: MDBH) announced board transitions effective February 1, 2026. Jeb Terry, Sr. was appointed to the board; Susanne L. Meline concluded her board service and will remain a shareholder and advocate. The company cited Terry's two decades in microcap life sciences investing and his leadership at Aberdeen Investment Management (2010–2025).
MDB said these changes support its strategy to scale a public venture platform that launches and finances early-stage, category-leading companies.
PatentVest (MDBH) released a PatentVest Pulse report on Jan 14, 2026 titled The Patent Battlefield, analyzing patent data across the $1.8 trillion space economy.
The study covers 1,450+ launch-related patent families and finds: SpaceX's IP points to Starlink as its core business rather than launch; Blue Origin is building early IP positions in cislunar markets; Rocket Lab relies heavily on acquired IP; and China and state-backed entities dominate global launch-related filings. The report frames these IP positions as indicators of IPO readiness, competitive risk, and likely value capture as the sector mainstreams.
MDB Capital Holdings (NASDAQ: MDBH) provided an operational update for the quarter ended September 30, 2025 and subsequent developments on November 20, 2025. Key items include an anticipated close this week of a $16.8 million private placement for Paulex Bio and a planned $20 million IPO for Buda Juice in December 2025. Management said the company expanded its pipeline of early-stage, category-disrupting companies, improved platform efficiency, and broadened investor relationships, including TCA Venture Group, Keiretsu Forum MST, and RIAs.
Management will host a Zoom webinar today at 4:30 p.m. ET led by CEO Christopher Marlett to review developments and answer questions; the live webcast is available via MDB investor relations.